Yates D H, Kharitonov S A, Barnes P J
Department of Thoracic Medicine, National Heart and Lung Institute, London, United Kingdom.
Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 1):1603-7. doi: 10.1164/ajrccm.154.6.8970342.
There is increasing evidence for the development of tolerance to the protective effects of inhaled beta 2-agonists against bronchoconstrictor stimuli. Animal studies have suggested that glucocorticoids protect against the down-regulation of beta 2-receptors after chronic exposure to beta 2-agonists. In a double-blind placebo-controlled crossover study in 12 patients with mild asthma, we investigated the effect of inhaled budesonide or identical placebo on the protection conferred by albuterol (200 micrograms) against methacholine-induced bronchoconstriction before and after treatment with the long-acting beta 2-agonist salmeterol. Patients were randomized to be treated for 3 wk with inhaled budesonide (800 micrograms twice a day) or placebo; salmeterol (50 micrograms twice a day) was added during the third week. Airway responsiveness to methacholine was measured 15 min after albuterol, both before and exactly 12 h [corrected] after the last salmeterol dose. Mean FEV1 increased significantly after 2 wk of budesonide (p < 0.05) and increased further after salmeterol (p < 0.05) compared with placebo. After 2 wk, the bronchoprotective effect of albuterol against methacholine was significantly greater with budesonide than with placebo (3.4 versus 2.4 doubling dilutions; p < 0.05), consistent with an improvement in airway hyperresponsiveness with budesonide therapy. However, regular salmeterol treatment for 1 wk significantly diminished the protection conferred by albuterol against methacholine challenge, both with budesonide and with placebo (-1.1 +/- 0.42 and -1.41 +/- 0.30 doubling dilutions, respectively). There was no significant difference in the loss of bronchoprotection seen with salmeterol between budesonide and placebo treatment periods. Our study suggests that even a high dose of an inhaled glucocorticoid fails to prevent the loss of bronchoprotection produced by regular beta 2-agonist therapy.
越来越多的证据表明,机体对吸入性β2激动剂针对支气管收缩刺激的保护作用会产生耐受性。动物研究提示,糖皮质激素可防止长期接触β2激动剂后β2受体下调。在一项针对12例轻度哮喘患者的双盲安慰剂对照交叉研究中,我们调查了吸入布地奈德或相同安慰剂对沙丁胺醇(200微克)在长效β2激动剂沙美特罗治疗前后针对乙酰甲胆碱诱发的支气管收缩所提供保护作用的影响。患者被随机分为两组,分别接受吸入布地奈德(800微克,每日两次)或安慰剂治疗3周;在第三周加用沙美特罗(50微克,每日两次)。在最后一次沙美特罗给药前及给药后12小时[校正后],在给予沙丁胺醇15分钟后测量气道对乙酰甲胆碱的反应性。与安慰剂相比,布地奈德治疗2周后平均第一秒用力呼气容积(FEV1)显著增加(p<0.05),沙美特罗治疗后进一步增加(p<0.05)。2周后,布地奈德组中沙丁胺醇针对乙酰甲胆碱的支气管保护作用显著大于安慰剂组(3.4倍稀释倍数对2.4倍稀释倍数;p<0.05),这与布地奈德治疗使气道高反应性改善一致。然而,常规沙美特罗治疗1周显著减弱了沙丁胺醇针对乙酰甲胆碱激发试验的保护作用,布地奈德组和安慰剂组均如此(分别为-1.1±0.42和-1.41±0.30倍稀释倍数)。布地奈德组和安慰剂治疗期之间,沙美特罗导致的支气管保护作用丧失无显著差异。我们的研究提示,即使是高剂量吸入糖皮质激素也无法防止常规β2激动剂治疗导致的支气管保护作用丧失。